Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUJCBT)

• Drug Name: Altiratinib Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 54576299
  CAS Number: CAS 1345847-93-9
  TTD Drug ID: DMUJCBT

Molecule-Related Drug Atlas

Drug(s) Targeting Tropomyosin-related kinase A (TrkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small cell lung cancer	2C25	Approved	[4]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
MIM-D3	DMZHN5B	Alzheimer disease	8A20	Phase 3	[6]
SNA-120	DMPN314	Plaque psoriasis	EA90.0	Phase 2	[7]
CT 327	DMQXL1T	Plaque psoriasis	EA90.0	Phase 2	[8]
TPX-0005	DM9FB2T	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
ONO-7579	DMXLPYE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[10]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
LOXO-195	DMDXFBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[12]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[13]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[14]
Tepotinib	DMUQ0E8	Non-small cell lung cancer	2C25	Approved	[15]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25.Y	Phase 3	[16]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[17]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[9]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[18]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[19]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[17]

Drug(s) Targeting NT-3 growth factor receptor (TrkC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small cell lung cancer	2C25	Approved	[4]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[20]
PMID28270021-Compound-WO2016054807Example1	DMD5QEL	Chronic pain	MG30	Patented	[21]
PMID28270010-Compound-Figure24-b	DM0QHLK	N. A.	N. A.	Patented	[3]
Pyrrolo[2,3-d]pyrimidine derivative 4	DME0WSR	Chronic pain	MG30	Patented	[21]
3-amino-5-benzyl-substituted indazole derivative 1	DMFDURZ	Chronic pain	MG30	Patented	[21]
PMID28270010-Compound-Figure5-1	DM2YAPJ	N. A.	N. A.	Patented	[3]
PMID28270021-Compound-WO2015042088Example4	DM6KXOQ	Chronic pain	MG30	Patented	[21]
PMID28270010-Compound-Figure5-2	DMK3GRZ	N. A.	N. A.	Patented	[3]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[22]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[23]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[12]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[24]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[25]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[26]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[27]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[13]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[28]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[29]

Drug(s) Targeting Angiopoietin 1 receptor (TEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AKB-9778	DMKNRYH	Diabetic macular edema	9B71.02	Phase 2	[30]
DCC-2036	DMJKFNU	Chronic myeloid leukaemia	2A20	Phase 1/2	[9]
CEP-11981	DMYDTJ6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[31]
ARRY-614	DMXD93K	Arthritis	FA20	Discontinued in Phase 1	[32]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[33]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[33]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[33]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[33]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[34]
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	DMFO8DR	Discovery agent	N.A.	Investigative	[35]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin 1 receptor (TEK)	TT9VGXW	TIE2_HUMAN	Inhibitor	[2]
NT-3 growth factor receptor (TrkC)	TTXABCW	NTRK3_HUMAN	Inhibitor	[3]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[2] , [3]
Tropomyosin-related kinase A (TrkA)	TTTDVOJ	NTRK1_HUMAN	Inhibitor	[3]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Antagonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040094)
• [2] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [3] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] National Cancer Institute Drug Dictionary (drug id 747694).
• [11] National Cancer Institute Drug Dictionary (drug id 766123).
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [13] Clinical pipeline report, company report or official report of Exelixis (2011).
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [16] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [18] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [20] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [21] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
• [22] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [23] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [24] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [25] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [26] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [27] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [29] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [30] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
• [32] Cmpany report (Arraybiopharma)
• [33] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [34] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
• [35] Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.